Larotrectinib plus radiation for thyroid cancer with NTRK fusion
Part of Cancer, Hormones & metabolism clinical trials.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 1 or older
- You have differentiated thyroid cancer, and your thyroid has been removed (thyroidectomy), plus standard local treatment for neck spread
- Your recent chest CT shows lung tumors that look measurable (many non-calcified nodules or enlarging/discrete nodules)
- Your tumor has an NTRK gene fusion (NTRK1, NTRK2, or NTRK3) on a certified test, and you do not have a known drug-resistance mutation
- You must be well enough to participate (Lansky/Karnofsky score at least 50)
- Your blood counts, kidneys, and liver blood tests must be within allowed limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.